• According to Transparency Market Research’s latest report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market for the historical period 2017–2018 and forecast period 2019–2027, growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs are the factors likely to boost the growth of High Potency Active Pharmaceutical Ingredients (HPAPI) market. However, containment of technical expertise in the hands of few major players and lack of universal regulatory policies and standards is poised to escalate the growth of High Potency Active Pharmaceutical Ingredients (HPAPI) market.
  • According to the report, the global High Potency Active Pharmaceutical Ingredients (HPAPI) market was valued at US$ 17.45 Bn in 2018 and is anticipated to expand at a CAGR of over 8.7% from 2019 to 2027
fa global high potency active pharmaceutical ingredients market

To know the scope of our report Get a Sample on High Potency Active Pharmaceutical Ingredient (HPAPI) Market

Growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs: Key Drivers of Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market

  • Pharmaceutical companies were skeptical in outsourcing manufacture of high potency APIs, and majority of the manufacturing was confined to captive or in-house. Major factor behind this was risk of patent infringement. However, as pharmaceutical companies started to expand geographical boundaries, they started experiencing shortage of HPAPIs. Furthermore, increasing cost of drug development and commercialization added to the financial burden. With developing regulatory and legal framework, outsourcing proved to be the most optimal option for HPAPI manufacturing.
  • Pharmaceutical companies can now focus on core business activities such as drug development and commercialization, while also take advantage of technical expertise at CMOs instead of investing in expensive HPAPI manufacturing setup.
  • Pharmaceutical companies have made significant investments in development of innovative drugs with targeted mode of action. Specific action and little or no side effects are major advantages for preference of such drugs. Various research articles published suggest that over 25% of the drugs in pipeline incorporate high potency active pharmaceutical ingredient (HPAPI). Currently only two antibody-drug conjugated drugs have been approved: Adcertis (Brentuximab vedotin) and Kadcyla (Trastuzumab emtansine). There are two other late stage candidates Inotuzumab ozogamicin (by, Pfizer) and IMMU-107 (by, Immunomedics). Several monoclonal antibody drugs are also expected to hit the market in the near future. Palivizumab, ofatumumab, KW-0761, and pembrolizumab are only a few examples of monoclonal antibody drugs in phase 3.
  • With increasing number of potential phase 3 drug candidates, demand for contract manufacturing of HPAPIs has increased significantly in the recent past, and is one of the major drivers of the global HPAPI market.

Get a glimpse of the in-depth analysis through our Report Brochure

Patent Expiry of Blockbuster Drugs Propel Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Growth

  • Patent expiry and subsequent launch of generic versions is a lucrative opportunity for pharmaceutical companies to expand product portfolio and tap profitable market segments in this technology driven market. Various biosimilar have been approved in Europe, while the U.S. FDA has approved only one biosimilar to date. Increase in research and development activities and constant attempts toward mimicking branded biological drugs would pave the way for introduction of cost-effective treatment alternatives.
  • Various blockbuster drugs are expected to loose patent protection in the near future, providing large opportunities in the biosimilar market. Avastin (bevacizumab), Herceptin (trastuzumab), Synagis (palivizumab), Erbitux (cetuximab), Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab) are some of the major drugs going off patent in the near future.

Containment of Technical Expertise in the Hands of Few Major Players to Hamper Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market

  • High potency API manufacturing is capital intensive and requires skilled technical know-how; this has been a major barrier for new entrants who wish to tap the lucrative HPAPI market. Currently, few major players exist who have built their own capabilities through mergers, acquisitions, partnerships, and research and development.
  • Hence, the global HPAPI manufacturing market is leaning toward consolidation of expertise in the hands of few global players. Lonza, Novasep, SAFC, Cambrex, Teva API, Dr. Reddy’s Laboratories, and WuXi are key players in the HPAPI market.

Lack of Universal Regulatory Policies and Standards to Restrain Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market

  • The high potency API market is a rapidly growing market with large numbers of players looking to invest in building capabilities for manufacturing of HPAPIs. HPAPIs are highly toxic to human body. Hence, high level of care is taken during manufacturing of these compounds. Despite these complications, there does not exist any specific occupational health, safety, and environmental protection regulations that cover manufacturing of HPAPIs.
  • Private organizations such as Merck, Lonza, and SafeBridge have taken initiative to classify HPAPIs and (occupational exposure limits) OELs. However, CMOs need to maintain manufacturing standards as per client requirements due to lack of a universal guidelines. Introduction of universal guidelines and manufacturing policies would also provide credibility to CMOs, thus helping pharmaceutical companies in outsourcing business.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Competitive Landscape

  • This report profiles major players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global High Potency Active Pharmaceutical Ingredients (HPAPI) market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are
    • Alkermes plc
    • Cambrex Corporation
    • Dr. Reddy's Laboratories
    • Lonza Group
    • Novasep
    • Novartis AG
    • Pfizer
    • Sigma-Aldrich Co. LLC.
    • WuXi AppTec
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries
    • Eli Lilly and Company
    • Abbvie.

Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Key Developments

Key players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global High Potency Active Pharmaceutical Ingredients (HPAPI) market. A few expansion strategies adopted by players operating in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are:

  • In April 2019, U.S. based Cambrex Corporation expanded its new facility high-potency API production in U.S.
  • In 2018, FDA approved 59 drugs, of that 42 were small molecules and 17 were biologics which accounts to about 28.8% of total approvals which has risen from 26.1% from the year 2017. Few biologic drugs approved in 2018 are Trogarzo, Ilumya, Crysvita, Aimovig, Poteligeo, Emgality, Libtayo and Takyzyro.

The report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market discussed individual strategies, followed by company profiles of manufacturers of High Potency Active Pharmaceutical Ingredients. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market

Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market – Segmentation

API Type

Synthetic

Biological

Manufacture Type

Captive

Contract

Drug Type

Branded

Generic

Therapeutic Application

Oncology Drugs

Anti-diabetic Drugs

Cardiovascular Drugs

Academic & Research Centers

Pharmaceutical Companies

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Type/Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, 2017–2027

5. Key Insights

    5.1. Value Chain Analysis

    5.2. Event Impact analysis

    5.3. Epidemiology of Cancer by Country/Sub-region

6. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by API Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

        6.3.1. Synthetic

        6.3.2. Biological

    6.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Product Type

7. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Manufacture Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

        7.3.1. Captive

        7.3.2. Contract

    7.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Manufacture Type

8. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Drug Type

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

        8.3.1. Branded

        8.3.2. Generic

    8.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Drug Type

9. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Therapeutic Application

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

        9.3.1. Oncology Drugs

        9.3.2. Anti-diabetic Drugs

        9.3.3. Cardiovascular Drugs

        9.3.4. CNS Drugs

        9.3.5. Musculoskeletal Drugs

        9.3.6. Other Drugs 

    9.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Therapeutic Application

10. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Region

    10.1. Key Findings

    10.2. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Country/Region

11. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

        11.2.1. Synthetic

        11.2.2. Biological

    11.3. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

        11.3.1. Captive

        11.3.2. Contract

    11.4. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

        11.4.1. Branded

        11.4.2. Generic

    11.5. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

        11.5.1. Oncology Drugs

        11.5.2. Anti-diabetic Drugs

        11.5.3. Cardiovascular Drugs

        11.5.4. CNS Drugs

        11.5.5. Musculoskeletal Drugs

        11.5.6. Other Drugs

    11.6. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

        11.7.1. By API Type

        11.7.2. By Manufacture Type

        11.7.3. By Drug Type

        11.7.4. By Therapeutic Application

        11.7.5. By Country

12. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

        12.2.1. Synthetic

        12.2.2. Biological

    12.3. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

        12.3.1. Captive

        12.3.2. Contract

    12.4. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

        12.4.1. Branded

        12.4.2. Generic

    12.5. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

        12.5.1. Oncology Drugs

        12.5.2. Anti-diabetic Drugs

        12.5.3. Cardiovascular Drugs

        12.5.4. CNS Drugs

        12.5.5. Musculoskeletal Drugs

        12.5.6. Other Drugs

    12.6. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

        12.7.1. By API Type

        12.7.2. By Manufacture Type

        12.7.3. By Drug Type

        12.7.4. By Therapeutic Application

        12.7.5. By Country/Sub-region

13. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

        13.2.1. Synthetic

        13.2.2. Biological

    13.3. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

        13.3.1. Captive

        13.3.2. Contract

    13.4. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

        13.4.1. Branded

        13.4.2. Generic

    13.5. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

        13.5.1. Oncology Drugs

        13.5.2. Anti-diabetic Drugs

        13.5.3. Cardiovascular Drugs

        13.5.4. CNS Drugs

        13.5.5. Musculoskeletal Drugs

        13.5.6. Other Drugs

    13.6. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

        13.7.1. By API Type

        13.7.2. By Manufacture Type

        13.7.3. By Drug Type

        13.7.4. By Therapeutic Application

        13.7.5. By Country/Sub-region

14. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

        14.2.1. Synthetic

        14.2.2. Biological

    14.3. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

        14.3.1. Captive

        14.3.2. Contract

    14.4. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

        14.4.1. Branded

        14.4.2. Generic

    14.5. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

        14.5.1. Oncology Drugs

        14.5.2. Anti-diabetic Drugs

        14.5.3. Cardiovascular Drugs

        14.5.4. CNS Drugs

        14.5.5. Musculoskeletal Drugs

        14.5.6. Other Drugs

    14.6. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

        14.7.1. By API Type

        14.7.2. By Manufacture Type

        14.7.3. By Drug Type

        14.7.4. By Therapeutic Application

        14.7.5. By Country/Sub-region

15. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

        15.2.1. Synthetic

        15.2.2. Biological

    15.3. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

        15.3.1. Captive

        15.3.2. Contract

    15.4. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

        15.4.1. Branded

        15.4.2. Generic

    15.5. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

        15.5.1. Oncology Drugs

        15.5.2. Anti-diabetic Drugs

        15.5.3. Cardiovascular Drugs

        15.5.4. CNS Drugs

        15.5.5. Musculoskeletal Drugs

        15.5.6. Other Drugs

    15.6. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

        15.7.1. By API Type

        15.7.2. By Manufacture Type

        15.7.3. By Drug Type

        15.7.4. By Therapeutic Application

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of companies)

    16.2. Market Share Analysis/Ranking By Company (2018)

    16.3. Company Profiles

        16.3.1. Alkermes plc,

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Growth Strategies

            16.3.1.3. SWOT Analysis. 

        16.3.2. Cambrex Corporation

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Growth Strategies

            16.3.2.3. SWOT Analysis. 

        16.3.3. Dr. Reddy's Laboratories

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Growth Strategies

            16.3.3.3. SWOT Analysis. 

        16.3.4. Lonza Group

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Growth Strategies

            16.3.4.3. SWOT Analysis. 

        16.3.5. Novasep

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Growth Strategies

            16.3.5.3. SWOT Analysis. 

        16.3.6. Novartis AG

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Growth Strategies

            16.3.6.3. SWOT Analysis. 

        16.3.7. Pfizer

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Growth Strategies

            16.3.7.3. SWOT Analysis. 

        16.3.8. Sigma-Aldrich Co. LLC.

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Growth Strategies

            16.3.8.3. SWOT Analysis. 

        16.3.9. WuXi AppTec

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Growth Strategies

            16.3.9.3. SWOT Analysis. 

List of Table

Table 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 07: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 08: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 09: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 10: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 11: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2027

Table 12: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 13: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 14: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 15: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 16: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 17: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 18: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 19: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 20: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 21: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 22: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 23: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 25: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 26: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 27: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 28: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 29: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 30: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 31: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 32: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 33: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 34: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 35: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 36: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figure

Figure 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Synthetic, 2017–2027 

Figure 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Biological, 2017–2027 

Figure 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 07: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 08: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Captive, 2017–2027 

Figure 09: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Contract, 2017–2027 

Figure 10: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 11: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 12: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oncology Drugs, 2017–2027 

Figure 13: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-diabetic Drugs, 2017–2027 

Figure 14: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cardiovascular Drug, 2017–2027 

Figure 15: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CNS Drugs, 2017–2027 

Figure 16: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Musculoskeletal Drugs, 2017–2027 

Figure 17: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027 

Figure 18: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 19: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 20: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017–2027

Figure 21: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017–2027

Figure 22: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 23: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Region, 2018 and 2027

Figure 24: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Region, 2019–2027

Figure 25: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 26: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 27: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 28: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 29: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 30: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 31: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 32: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 33: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country, 2018 and 2027

Figure 34: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country, 2019–2027

Figure 35: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 36: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 37: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 38: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 39: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 40: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 41: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 42: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 43: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 44: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 45: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 46: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 47: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 48: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 49: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 50: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 51: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 52: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 53: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 54: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 55: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 56: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 57: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 58: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 59: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 60: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 61: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 62: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 63: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 64: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 65: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 66: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 67: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 68: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 69: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 70: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 71: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 72: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 73: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 74: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 75: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 76: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 77: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 78: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 79: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share, by Company, 2018 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

High Potency Active Pharmaceutical Ingredient (HPAPI) Market